Skip to main content
. Author manuscript; available in PMC: 2023 Oct 10.
Published in final edited form as: Arthritis Care Res (Hoboken). 2020 May 11;72(6):744–760. doi: 10.1002/acr.24180

Table 3.

Recommendations for all patients taking urate-lowering therapy (ULT)*

Recommendation PICO question Certainty of evidence
For all patients taking ULT, we strongly recommend a treat-to-target strategy of ULT dose management that includes dose titration and subsequent dosing guided by serial SU values to achieve an SU target over a fixed, standard-dose ULT strategy. 13 Moderate
For all patients taking ULT, we strongly recommend continuing ULT to achieve and maintain an SU target of <6 mg/dl over no target. 14 High
For all patients taking ULT, we conditionally recommend delivery of an augmented protocol of ULT dose management by nonphysician providers to optimize the treat-to-target strategy that includes patient education, shared decision-making, and treat-to-target protocol. 8 Moderate
We conditionally recommend continuing ULT indefinitely over stopping ULT. 19 Very low

Strongly recommend Conditionally recommend Strongly recommend against Conditionally recommend against
*

PICO = population, intervention, comparator, outcomes; SU = serum urate.